Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets

Aspire Biopharma Holdings, Inc. (ASBPW)

NCM

$0.02+0.01 (+31.87%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
P/E (TTM)
EPS
Div Yield
52W Range
$0.02–$0.02
Beta
0.15

Company overview

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Peers in industry

Aspire Biopharma Holdings, Inc. has no peer companies in this window.

Recent press releases

April 2026

3 months agoS-1/A

Aspire Biopharma Holdings, Inc. — S-1/A Filing

ASBPWAspire Biopharma Holdings, Inc.

# 🧾 What This Document Is This is an **amended registration statement (S-1/A)**. Think of it as the final paperwork needed to let certain investors sell the shares they recently bought from the company. * **Why it exists:** Aspire Biopharma raised $11 million in February 2026 by selling special

Read summaryView on SEC EDGAR

March 2026

4 months ago10-K

Aspire Biopharma Holdings, Inc. — 10-K Filing

ASBPWAspire Biopharma Holdings, Inc.

# 🧾 What This Document Is This is Aspire Biopharma's **10-K annual report**, the comprehensive yearly filing required by the SEC for public companies. It’s a deep dive into their business operations, financial performance, and the risks they face. Think of it as the company's official report card f

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Aspire Biopharma Holdings, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
UBS Group AG$331,963
2,514,873 sh+32727.0%
688,143 sh+2252.1%
232,661 sh-50.8%
813,427 sh0.0%
428,552 sh0.0%
265,471 sh+853.2%
247,555 sh-1.0%
202,897 sh0.0%

People at Aspire Biopharma Holdings, Inc.

All people →

No officers or directors have been indexed for Aspire Biopharma Holdings, Inc..

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$15.9M
06/25
NI -$2.0M
09/25
$1.9K
NI -$1.9M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.04
Prior: $-0.04
Revenue sparkline